Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. following a significant decline in its stock price due to disappointing performance metrics [2][4]. Group 1: Company Performance - On January 9, 2026, Beta Bionics' shares dropped approximately $11.85, or 37.04%, closing at $20.14 after the company reported preliminary fourth-quarter 2025 performance metrics that did not meet market expectations [4]. - The decline was attributed to lower-than-expected new patient starts for its iLet automated insulin delivery system, raising concerns about near-term adoption trends and revenue growth [4]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP, a prominent national securities law firm, is encouraging investors who suffered significant losses in Beta Bionics stock or options to reach out for potential claims [1][2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities claims against Beta Bionics, Inc. following a significant decline in its stock price due to disappointing performance metrics [2][3][4]. Company Performance - On January 9, 2026, Beta Bionics disclosed preliminary fourth-quarter 2025 performance metrics that fell short of market expectations, particularly reporting lower-than-anticipated new patient starts for its iLet automated insulin delivery system [3][5]. - As a result of this news, Beta Bionics' stock price dropped approximately $11.85, or 37.04%, closing at $20.14 on the same day [4][5]. Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Beta Bionics stock or options to discuss their legal rights and options [1][2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. following a significant decline in its stock price due to disappointing performance metrics [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported preliminary fourth-quarter 2025 performance metrics that did not meet market expectations, leading to a sharp decline in its stock price [5]. - The company experienced lower-than-anticipated new patient starts for its iLet automated insulin delivery system, raising concerns about near-term adoption trends and revenue growth [5]. Group 2: Stock Market Reaction - Following the disappointing performance disclosure, Beta Bionics' stock fell approximately $11.85, or 37.04%, closing at $20.14 on January 9, 2026 [5]. Group 3: Legal Actions - Investors who suffered significant losses in Beta Bionics are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][6].

Core Viewpoint - Faruqi & Faruqi, LLP has initiated an investigation into Beta Bionics, Inc. following a significant decline in its stock price due to disappointing preliminary fourth-quarter performance metrics [1] Group 1: Company Performance - Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, raising concerns about near-term adoption trends and revenue growth [1] - On January 9, 2026, Beta Bionics' stock fell approximately $11.85, or 37.04%, closing at $20.14 [1] Group 2: Legal Actions - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Beta Bionics stock or options to discuss their legal rights [1] - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [1]

Core Insights - Beta Bionics experienced a significant decline in stock price following the release of preliminary fourth-quarter 2025 performance metrics that did not meet market expectations [1] - The company reported lower-than-expected new patient starts for its iLet automated insulin delivery system, raising concerns among investors about short-term adoption trends and revenue growth [1] - On January 9, 2026, Beta Bionics' stock fell approximately $11.85, or 37.04%, closing at $20.14 [1]

Core Viewpoint - Beta Bionics, Inc. has faced significant stock declines following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped approximately $11.85, or 37.04%, closing at $20.14 on the same day [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics for investors who suffered significant losses due to the stock's decline [2][4]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Beta Bionics, Inc. has faced significant stock decline following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped by approximately $11.85, or 37.04%, closing at $20.14 [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics due to the significant losses suffered by investors [2]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].